Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 20/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8699763 | 1.00 | LTB4R (0.61) | LTB4R | |
| SCHEMBL7022636 | 0.99 | LTB4R (0.60) | LTB4R | |
| SCHEMBL7022628 | 0.99 | LTB4R (0.60) | LTB4R | |
| SCHEMBL7023827 | 0.90 | LTB4R (0.59) | LTB4R | |
| SCHEMBL7023822 | 0.90 | LTB4R (0.59) | LTB4R | |
| Hydrochloric Acid SCHEMBL7023840 | 0.89 | LTB4R (0.58) | LTB4R | |
| Hydrochloric Acid SCHEMBL7023839 | 0.89 | LTB4R (0.58) | LTB4R | |
| SCHEMBL8694497 | 0.89 | LTB4R (0.75) | LTB4R | |
| SCHEMBL8757578 | 0.89 | LTB4R (0.75) | LTB4R | |
| Hydrochloric Acid SCHEMBL8698525 | 0.88 | LTB4R (0.74) | LTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5726315-A | Certain 3-hydroxy-6-hydroxymethyl-pyridine intermediates | SMITHKLINE BEECHAM PLC (GB) | 1998-03-10 | — | — | US | disclosed |
| US-5656636-A | TREATING PSORIASIS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-12 | — | — | US | disclosed |
| US-5646286-A | Palladium catalyzed vinylic substitution reactions with 2-substituted-pyridines | SMITHKLINE BEECHAM PLC (GB) | 1997-07-08 | — | — | US | disclosed |
| US-5633258-A | Pyridine compounds for treating leukotriene-related diseases | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-27 | — | — | US | disclosed |
| US-5631262-A | Pyridine compounds for treating leukotriene-related diseases | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-20 | — | — | US | disclosed |
| EP-0705249-B1 | PALLADIUM CATALYZED VINYLIC SUBSTITUTION REACTIONS WITH 2-SUBSTITUTED-PYRIDINES | SMITHKLINE BEECHAM PLC (GB) | 1997-05-14 | — | — | EP | disclosed |
| EP-0705249-A1 | PALLADIUM CATALYZED VINYLIC SUBSTITUTION REACTIONS WITH 2-SUBSTITUTED-PYRIDINES | SMITHKLINE BEECHAM PLC (GB) | 1996-04-10 | — | — | EP | disclosed |
| EP-0675718-A1 | SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-10-11 | — | — | EP | disclosed |
| EP-0675718-A4 | SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS LEUKOTRIENE ANTAGONISTS. | SMITHKLINE BEECHAM CORP (US) | 1995-08-22 | — | — | EP | disclosed |
| WO-1995000487-A1 | PALLADIUM CATALYZED VINYLIC SUBSTITUTION REACTIONS WITH 2-SUBSTITUTED-PYRIDINES | SMITHKLINE BEECHAM PLC (GB) | 1995-01-05 | — | — | WO | disclosed |
| WO-1994014442-A1 | SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-07-07 | — | — | WO | disclosed |
| EP-0604529-A1 | PYRIDINE COMPOUNDS FOR TREATING LEUKOTRIENE-RELATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1994-07-06 | — | — | EP | disclosed |
| EP-0593464-A1 | BENZOIC ACID DERIVATIVES and their use as LTB4 inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1994-04-27 | — | — | EP | disclosed |
| WO-1993011768-A1 | PYRIDYL COMPOUNDS FOR PSORIASIS TREATMENT | SMITHKLINE BEECHAM CORPORATION (US) | 1993-06-24 | — | — | WO | disclosed |
| WO-1993006085-A1 | PYRIDINE COMPOUNDS FOR TREATING LEUKOTRIENE-RELATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1993-04-01 | — | — | WO | disclosed |
| EP-0593464-A4 | BENZOIC ACID DERIVATIVES. | SMITHKLINE BEECHAM CORP (US) | 1993-02-12 | — | — | EP | disclosed |
| WO-1991018601-A1 | BENZOIC ACID DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 1991-12-12 | — | — | WO | disclosed |